Sopharma Profit Up 35.1% In First Half

The 1H profit of Sopharma () surged 35.1% to 19.5 mln leva (9.970 mln euros), against 14.18 mln leva (7.250 mln euros) a year ago, shows the company's non-consolidated report filed with the BSE yesterday.

Revenues are up 8.05% to 82.54 mln leva (42.202 mln euros) from 76.39 mln leva (39.057 mln euros) a year ago, the report also reveals. The company attributes the good result to higher revenues from core activity and more specifically to good production sales.

The positive difference from changes in currency exchange rates declined significantly - from 3.66 mln leva a year ago, to 774,000 leva, as well as that from interest rates - down from 1.63 mln leva to 688,000 leva.

Costs are slightly up – by 2.6% from 59.71 mln leva (30.529 mln euros) to 61.25 mln leva (31.316 mln euros).

The increase in core cativity costs is neutralized to a large extent by the negative difference from changes in currency exchange rates – from 4.12 mln leva a year ago to 1.3 mln leva.

The company has a core capital in the amount of 132 mln leva (67.490 mln euros), and own capital in the amount of 189.91 mln leva (97.099 mln euros), according to 1H report.

At a general meeting held 26 June, shareholders approved gross dividend distribution in the amount of 0.10 leva per share (0.093 leva net dividend).

The stock started today's trade session positively. 4,500 shares have changed hands so far today at an average of 7.36 leva per share, or 0.7% up from yesterday. Bids are currently at 7.36 leva and asks at 7.4 leva.

Facebook Коментари

Добави коментар

Екипът на Ви благодари, че използвате кирилица за вашите коментари.
В случай, че коментарът Ви съдържа нецензурни квалификации и лични нападки или обиди на расова, сексуална, етническа или верска основа, той ще бъде изтрит от модератора на сайта.

Абонирайте се за електронния
информационен бюлетин на